Insider Buying: Hikma Pharmaceuticals (LON:HIK) Insider Acquires 20,000 Shares of Stock
Hikma Pharmaceuticals (LON:HIK) insider Sigurdur Olafsson bought 20,000 shares of the stock in a transaction on Wednesday, May 30th. The shares were acquired at an average cost of GBX 1,309 ($17.43) per share, for a total transaction of £261,800 ($348,555.45).
Shares of LON HIK traded up GBX 7 ($0.09) on Thursday, reaching GBX 1,427 ($19.00). 401,217 shares of the company’s stock traded hands, compared to its average volume of 822,138. Hikma Pharmaceuticals has a 12 month low of GBX 814.20 ($10.84) and a 12 month high of GBX 2,346 ($31.23).
Several brokerages recently issued reports on HIK. Barclays reiterated an “underweight” rating on shares of Hikma Pharmaceuticals in a research report on Monday, May 21st. Peel Hunt cut their price target on shares of Hikma Pharmaceuticals from GBX 1,180 ($15.71) to GBX 1,160 ($15.44) and set a “hold” rating for the company in a research report on Tuesday, March 20th. Jefferies Financial Group reaffirmed a “hold” rating and set a GBX 997 ($13.27) price objective on shares of Hikma Pharmaceuticals in a research note on Friday, May 18th. JPMorgan Chase & Co. upped their price objective on shares of Hikma Pharmaceuticals from GBX 1,000 ($13.31) to GBX 1,050 ($13.98) and gave the company a “neutral” rating in a research note on Thursday, March 15th. Finally, Morgan Stanley increased their price target on shares of Hikma Pharmaceuticals from GBX 1,000 ($13.31) to GBX 1,050 ($13.98) and gave the stock an “equal weight” rating in a research note on Thursday, March 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of GBX 1,131.70 ($15.07).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.